Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
magrolimab + nivolumab + FOLFOX + bevacizumab
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This combination comprises four active agents: **magrolimab**, a monoclonal antibody targeting CD47 to enhance macrophage-mediated phagocytosis of cancer cells; **nivolumab**, a PD-1 immune checkpoint inhibitor that potentiates T cell-mediated anti-tumor activity; **FOLFOX**, a chemotherapy regimen consisting of 5-fluorouracil, leucovorin, and oxaliplatin with cytotoxic and antiproliferative effects on tumor cells; and **bevacizumab**, a monoclonal antibody targeting VEGF-A to inhibit tumor angiogenesis. The regimen is under clinical investigation for advanced or metastatic colorectal cancer, particularly in settings where patients are unresectable or have recurrent disease[1][3][5].
- Other names
- magrolimab + nivolumab + FOLFOX + bevacizumab
02
Targets
CD47 (Cluster of Differentiation 47)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)DNA
Beyond the preview
Go deeper on magrolimab + nivolumab + FOLFOX + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on magrolimab + nivolumab + FOLFOX + bevacizumab.